Osmotica Pharmaceuticals Plc

NASDAQ:OSMT  
2.91
-0.06 (-2.02%)
Earnings Announcements

Osmotica Pharmaceuticals PLC Reports Fourth Quarter And Full Year 2020 Results

Published: 03/30/2021 20:31 GMT
Osmotica Pharmaceuticals Plc (OSMT) - Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update.
Q4 Revenue $34.5 Million Versus Refinitiv Ibes Estimate of $35.6 Million.
Osmotica Pharmaceuticals - Cash, Equivalents Were $114.1 Million, and Debt (net of Deferred Financing Costs) Was $219.5 Million As of Dec 31, 2020.
Initiated Strategic Review in Q4.
Revenue is expected to be $30.65 Million
Adjusted EPS is expected to be -$0.24

Next Quarter Revenue Guidance is expected to be $30.65 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.